Skip to main content
Molecular Metabolism logoLink to Molecular Metabolism
. 2024 Sep 5;89:102023. doi: 10.1016/j.molmet.2024.102023

Corrigendum to “Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: effects on weight loss and safety in adults with overweight or obesity” [Mol Metab 78 (2023) 101801]

Martin Haljeta Friedrichsen 1,, Lars Endahl 1, Frederik Flindt Kreiner 1, Ronald Goldwater 2, Martin Kankam 3, Søren Toubro 1, Sune Boris Nygård 1
PMCID: PMC11415713  PMID: 39245214

In the original version of this manuscript, Table S2B was inadvertently omitted from the Supplementary Data. This table provides baseline characteristics data by dose level, for the multiple ascending dose trial. The corrected supplementary file, now including Table S2B, is available with this corrigendum. Please note that all data, findings, and conclusions of this study have not been affected by the corrigendum. The authors would like to apologise for any inconvenience caused.

Footnotes

Appendix A

Supplementary data to this article can be found online at https://doi.org/10.1016/j.molmet.2024.102023.

Appendix A. Supplementary data

The following is/are the supplementary data to this article:

Multimedia component 1
mmc1.docx (1.9MB, docx)

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Multimedia component 1
mmc1.docx (1.9MB, docx)

Articles from Molecular Metabolism are provided here courtesy of Elsevier

RESOURCES